靶向B细胞成熟抗原的CAR-T细胞疗法对复发/难治性多发性骨髓瘤有效,包括体能状态差的患者
这项开放标签、单臂、I/II期临床试验评估了抗B细胞成熟抗原(BCMA)CAR-T细胞(HDS269B)治疗49例复发/难治性多发性骨髓瘤(RRMM)患者的疗效,其中20例ECOG评分为3-4级。输注HDS269B(9×10^6 CAR+细胞/kg)后,17例(34.69%)发生细胞因子释放综合征,客观缓解率(ORR)为77%,完全缓解(CR)率为47%。中位无进展生存期(PFS)为10个月(95%CI 5.3-14.7),中位总生存期(OS)为29个月(95%CI 10.0-48.0)。
要点
- HDS269B在RRMM患者中ORR为77%,CR率为47%。
- ECOG 0-2级与3-4级患者ORR分别为79.31%和75.0%。
- ECOG 3-4级患者中位PFS为4个月(95%CI 0-11.7),中位OS为10.5个月(95%CI 0-22)。
核心结论
- HDS269B疗法对RRMM患者安全有效,即使是ECOG 3-4级患者。
研究设计与样本
- 开放标签、单臂、I/II期临床试验,纳入49例复发/难治性多发性骨髓瘤患者,其中20例ECOG评分为3-4级。
主要发现
- 输注HDS269B(9×10^6 CAR+细胞/kg)后,17例(34.69%)发生细胞因子释放综合征,其中1-2级14例(28.57%),3级3例(6.12%)。
- 客观缓解率(ORR)为77%,完全缓解(CR)率为47%。
- 15例患者持续缓解超过12个月,1例患者缓解超过38个月。
- 中位无进展生存期(PFS)为10个月(95%CI 5.3-14.7),中位总生存期(OS)为29个月(95%CI 10.0-48.0);12个月PFS率为41.64%,18个月OS率为62.76%。
- ECOG 0-2级与3-4级患者ORR分别为79.31%(23/29)和75.0%(15/20),中位PFS分别为15个月(95%CI 5.4-24.6)和4个月(95%CI 0-11.7);ECOG 0-2级患者OS未达到,ECOG 3-4级患者中位OS为10.5个月(95%CI 0-22)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this open-label, single-arm, phase I/II clinical trial, we evaluated the efficacy of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) therapy in 49 relapsed/refractory multiple myeloma (RRMM) patients, including 20 with Eastern Cooperative Oncology Group (ECOG) grade 3-4. After HDS269B infusion (9 × 106 CAR+ cells/kg), 17 patients (34.69%, 11 ECOG 0-2, 6 ECOG 3-4) developed cytokine release syndrome [grade 1-2: 14 patients (28.57%); grade 3: 3 patients (6.12%)]. The objective response rate (ORR) was 77%, with a complete response (CR) achieved in 47%. Ongoing response >12 months occurred in 15 patients, and was extended beyond 38 months in one patient. The median progression-free survival (PFS) and overall survival (OS) were 10 months (95% CI 5.3-14.7) and 29 months (95% CI 10.0-48.0), respectively. The PFS (12 months) and OS (18 months) rates were 41.64% and 62.76%, respectively. In patients with ECOG 0-2 and 3-4, ORR was 79.31% (23/29) and 75.0% (15/20) and PFS were 15 months (95% CI 5.4-24.6) and 4 months (95% CI 0-11.7), respectively. OS was not reached in ECOG 0-2 patients, but was 10.5 months (95% CI 0-22) in ECOG 3-4 patients. Single-cell sequencing indicated that treatment efficacy might be related to mTORC1 signaling. Thus, HDS269B therapy is safe and effective for RRMM patients, even those with ECOG 3-4.
引用
- Du J, Wei R, Jiang S, et al. CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status. Am J Hematol. 2022. PMID: 35488407. doi:10.1002/ajh.26583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。